Citius Oncology Price/Book Ratio 2023-2022 | CTOR

Citius Oncology price/book ratio from 2023 to 2022. Price/book ratio can be defined as

Citius Oncology Price/Book Ratio 2023-2022 | CTOR

Citius Oncology price/book ratio from 2023 to 2022. Price/book ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$180.1B
Regeneron Pharmaceuticals (REGN)$127.1B
Vertex Pharmaceuticals (VRTX)$126.3B
Gilead Sciences (GILD)$103.5B
Bristol Myers Squibb (BMY)$101.3B
CSL (CSLLY)$97.4B
GSK (GSK)$90.3B
Alnylam Pharmaceuticals (ALNY)$34.7B
Argenex SE (ARGX)$32.2B
BioNTech SE (BNTX)$29.4B
Biogen (BIIB)$29.1B
Moderna (MRNA)$26.6B
Illumina (ILMN)$20.6B
BeiGene (BGNE)$19.1B
Genmab (GMAB)$17.6B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$12.8B
Incyte (INCY)$12.8B
Vaxcyte (PCVX)$12.8B
Insmed (INSM)$12.6B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.6B
Legend Biotech (LEGN)$9.4B
Bio-Rad Laboratories (BIO.B)$9.1B
Roivant Sciences (ROIV)$8.9B
Ascendis Pharma (ASND)$8.1B
Halozyme Therapeutics (HALO)$8B
Intra-Cellular Therapies (ITCI)$8B
Repligen (RGEN)$7.8B